These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 9736927)
41. A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa. Sakharkar KR; Sakharkar MK; Chow VT In Silico Biol; 2004; 4(3):355-60. PubMed ID: 15724285 [TBL] [Abstract][Full Text] [Related]
42. Bioassays in natural product research - strategies and methods in the search for anti-inflammatory and antimicrobial activity. Strömstedt AA; Felth J; Bohlin L Phytochem Anal; 2014; 25(1):13-28. PubMed ID: 24019222 [TBL] [Abstract][Full Text] [Related]
43. Future potential for anti-infectives from bacteria - how to exploit biodiversity and genomic potential. Müller R; Wink J Int J Med Microbiol; 2014 Jan; 304(1):3-13. PubMed ID: 24119567 [TBL] [Abstract][Full Text] [Related]
44. Targeting virulence: a new paradigm for antimicrobial therapy. Clatworthy AE; Pierson E; Hung DT Nat Chem Biol; 2007 Sep; 3(9):541-8. PubMed ID: 17710100 [TBL] [Abstract][Full Text] [Related]
45. From bacterial genomes to novel antibacterial agents: discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzae. Lerner CG; Hajduk PJ; Wagner R; Wagenaar FL; Woodall C; Gu YG; Searle XB; Florjancic AS; Zhang T; Clark RF; Cooper CS; Mack JC; Yu L; Cai M; Betz SF; Chovan LE; McCall JO; Black-Schaefer CL; Kakavas SJ; Schurdak ME; Comess KM; Walter KA; Edalji R; Dorwin SA; Smith RA; Hebert EJ; Harlan JE; Metzger RE; Merta PJ; Baranowski JL; Coen ML; Thornewell SJ; Shivakumar AG; Saiki AY; Soni N; Bui M; Balli DJ; Sanders WJ; Nilius AM; Holzman TF; Fesik SW; Beutel BA Chem Biol Drug Des; 2007 Jun; 69(6):395-404. PubMed ID: 17581233 [TBL] [Abstract][Full Text] [Related]
46. Use of genetic and chemical synthetic lethality as probes of complexity in bacterial cell systems. Klobucar K; Brown ED FEMS Microbiol Rev; 2018 Jan; 42(1):. PubMed ID: 29069427 [TBL] [Abstract][Full Text] [Related]
47. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs. Kim W; Hendricks GL; Lee K; Mylonakis E Expert Opin Drug Discov; 2017 Jun; 12(6):625-633. PubMed ID: 28402221 [TBL] [Abstract][Full Text] [Related]
48. The targets of currently used antibacterial agents: lessons for drug discovery. Lange RP; Locher HH; Wyss PC; Then RL Curr Pharm Des; 2007; 13(30):3140-54. PubMed ID: 17979755 [TBL] [Abstract][Full Text] [Related]
50. A novel in vivo model to screen antimicrobial compounds. Osman K; Khan NA Int J Antimicrob Agents; 2010 Sep; 36(3):288-9. PubMed ID: 20430591 [No Abstract] [Full Text] [Related]
51. Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics. Rachakonda S; Cartee L Curr Med Chem; 2004 Mar; 11(6):775-93. PubMed ID: 15032731 [TBL] [Abstract][Full Text] [Related]
52. Novel Insight from Computational Virtual Screening Depict the Binding Potential of Selected Phytotherapeutics Against Probable Drug Targets of Clostridium difficile. Kamath S; Skariyachan S Interdiscip Sci; 2018 Sep; 10(3):583-604. PubMed ID: 28217823 [TBL] [Abstract][Full Text] [Related]
53. [Prospects for development of new antituberculous drugs]. Tomioka H Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850 [TBL] [Abstract][Full Text] [Related]
54. In silico identification of putative drug targets from different metabolic pathways of Aeromonas hydrophila. Sharma V; Gupta P; Dixit A In Silico Biol; 2008; 8(3-4):331-8. PubMed ID: 19032165 [TBL] [Abstract][Full Text] [Related]
55. Draft genome sequence, disease-resistance genes, and phenotype of a Paenibacillus terrae strain (NK3-4) with the potential to control plant diseases. Yu WQ; Zheng GP; Qiu W; Yan FC; Liu WZ; Liu WX Genome; 2018 Oct; 61(10):725-734. PubMed ID: 30184440 [TBL] [Abstract][Full Text] [Related]
56. DNA sequence sampling of the Streptococcus pneumoniae genome to identify novel targets for antibiotic development. Baltz RH; Norris FH; Matsushima P; DeHoff BS; Rockey P; Porter G; Burgett S; Peery R; Hoskins J; Braverman L; Jenkins I; Solenberg P; Young M; McHenney MA; Skatrud PL; Rosteck PR Microb Drug Resist; 1998; 4(1):1-9. PubMed ID: 9533720 [TBL] [Abstract][Full Text] [Related]